Yes, most multivitamins do not interfere with dolutegravir absorption. However, if the supplement contains high levels of calcium, iron, or magnesium, it is advisable to separate the doses by at least two hours to avoid reduced drug exposure.
Dolutegravir is not screened for in standard occupational drug-testing panels, so Tivicay will not cause a positive result for illicit substances.
Both regions market the same 50 mg tablet formulation, but labeling, packaging, and the regulatory authority differ (MHRA in the UK versus FDA in the US). The clinical data supporting use are consistent across regions.
A persistent or spreading rash warrants prompt medical evaluation. Severe skin reactions can be serious, and a clinician may need to discontinue the medication and consider alternative therapy.
Yes, you may travel with your medication, but it is advisable to keep the tablets in their original packaging with a copy of the prescription. Some countries require a doctor’s note for personal import of prescription medicines.
St John’s wort is a strong inducer of CYP3A4 and UGT1A1, which can lower dolutegravir concentrations and compromise viral suppression. Avoid co-administration unless a specialist adjusts the dose and monitors viral load closely.
Most patients achieve an undetectable viral load within 12 weeks of consistent therapy, provided adherence is high and the regimen includes appropriate companion antiretrovirals.
Dolutegravir does not directly affect bone mineral density. However, some HIV regimens that include tenofovir may impact bone health; discuss bone-protective strategies with your clinician if you have osteoporosis.
In the United Kingdom, Tivicay tablets are white, round, and debossed with “T” on one side and “50 mg” on the opposite side. The imprint helps distinguish them from other medications.
Dolutegravir has a high barrier to resistance and a convenient once-daily dosing schedule, which can simplify treatment for many patients. Clinical guidelines often recommend it as a first-line option when no contraindications exist.
Tivicay is a prescription medication that contains dolutegravir as its active component. It belongs to the class of antiretroviral agents known as integrase strand transfer inhibitors (INSTIs) and is used in the treatment of Human Immunodeficiency Virus (HIV) infection. In the United Kingdom, Tivicay is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is supplied as a 50 mg tablet for oral use.
Dolutegravir blocks the activity of the HIV integrase enzyme, which is essential for the virus to insert its genetic material into the DNA of human immune cells. By preventing this step, Tivicay stops the replication cycle of HIV, leading to a reduction in viral load and allowing the immune system to recover.
Key pharmacological points include:
Dolutegravir is absorbed well from the gastrointestinal tract, with an oral bioavailability of approximately 64 % when taken with food. It is primarily metabolised by UDP-glucuronosyltransferase 1A1 (UGT1A1) and, to a lesser extent, by CYP3A4, and is eliminated mainly in the feces.
In the UK, Tivicay is approved for the following indications, as defined by the MHRA:
Tivicay is intended for adult patients (≥ 18 years) living with HIV-1. It is not approved for the treatment of HIV-2 infection.
This article provides educational information about Tivicay and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
